Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression

Standard

Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression : A Randomized Clinical Trial. / Schramm, Elisabeth; Kriston, Levente; Zobel, Ingo; Bailer, Josef; Wambach, Katrin; Backenstrass, Matthias; Klein, Jan Philipp; Schoepf, Dieter; Schnell, Knut; Gumz, Antje; Bausch, Paul; Fangmeier, Thomas; Meister, Ramona; Berger, Mathias; Hautzinger, Martin; Härter, Martin.

in: JAMA PSYCHIAT, Jahrgang 74, Nr. 3, 01.03.2017, S. 233-242.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Schramm, E, Kriston, L, Zobel, I, Bailer, J, Wambach, K, Backenstrass, M, Klein, JP, Schoepf, D, Schnell, K, Gumz, A, Bausch, P, Fangmeier, T, Meister, R, Berger, M, Hautzinger, M & Härter, M 2017, 'Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression: A Randomized Clinical Trial', JAMA PSYCHIAT, Jg. 74, Nr. 3, S. 233-242. https://doi.org/10.1001/jamapsychiatry.2016.3880

APA

Schramm, E., Kriston, L., Zobel, I., Bailer, J., Wambach, K., Backenstrass, M., Klein, J. P., Schoepf, D., Schnell, K., Gumz, A., Bausch, P., Fangmeier, T., Meister, R., Berger, M., Hautzinger, M., & Härter, M. (2017). Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression: A Randomized Clinical Trial. JAMA PSYCHIAT, 74(3), 233-242. https://doi.org/10.1001/jamapsychiatry.2016.3880

Vancouver

Bibtex

@article{50076ca6179f4194bb4bba4f75edbb3a,
title = "Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression: A Randomized Clinical Trial",
abstract = "Importance: Chronic depression is a highly prevalent and disabling disorder. There is a recognized need to assess the value of long-term disorder-specific psychotherapy.Objective: To evaluate the efficacy of the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) compared with that of nonspecific supportive psychotherapy (SP).Design, Setting, and Participants: A prospective, multicenter, evaluator-blinded, randomized clinical trial was conducted among adult outpatients with early-onset chronic depression who were not taking antidepressant medication. Patients were recruited between March 5, 2010, and October 16, 2012; the last patient finished treatment on October 14, 2013. Data analysis was conducted from March 5, 2014, to October 27, 2016.Interventions: The treatment included 24 sessions of CBASP or SP for 20 weeks in the acute phase, followed by 8 continuation sessions during the next 28 weeks.Main Outcomes and Measures: The primary outcome was symptom severity after 20 weeks (blinded observer ratings) as assessed by the 24-item Hamilton Rating Scale for Depression (HRSD-24). Secondary outcomes were rates of response (reduction in HRSD-24 score of ≥50% from baseline) and remission (HRSD-24 score ≤8), as well as self-assessed ratings of depression, global functioning, and quality of life.Results: Among 622 patients assessed for eligibility, 268 were randomized: 137 to CBASP (96 women [70.1%] and 41 men [29.9%]; mean [SD] age, 44.7 [12.1] years) and 131 to SP (81 women [61.8%] and 50 men [38.2%]; mean [SD] age, 45.2 [11.6] years). The mean (SD) baseline HRSD-24 scores of 27.15 (5.49) in the CBASP group and 27.05 (5.74) in the SP group improved to 17.19 (10.01) and 20.39 (9.65), respectively, after 20 weeks, with a significant adjusted mean difference of -2.51 (95% CI, -4.16 to -0.86; P = .003) and a Cohen d of 0.31 in favor of CBASP. After 48 weeks, the HRSD-24 mean (SD) scores were 14.00 (9.72) for CBASP and 16.49 (9.96) for SP, with an adjusted difference of -3.13 (95% CI, -5.01 to -1.25; P = .001) and a Cohen d of 0.39. Patients undergoing CBASP were more likely to reach response (48 of 124 [38.7%] vs 27 of 111 [24.3%]; adjusted odds ratio, 2.02; 95% CI, 1.09 to 3.73; P = .03) or remission (27 of 124 [21.8%] vs 14 of 111 [12.6%]; adjusted odds ratio, 3.55; 95% CI, 1.61 to 7.85; P = .002) after 20 weeks. Patients undergoing CBASP showed significant advantages in most other secondary outcomes.Conclusions and Relevance: Highly structured specific psychotherapy was moderately more effective than nonspecific therapy in outpatients with early-onset chronic depression who were not taking antidepressant medication. Adding an extended phase to acute psychotherapy seems promising in this population.Trial Registration: clinicaltrials.gov Identifier: NCT00970437.",
keywords = "Adult, Ambulatory Care, Chronic Disease, Cognitive Therapy, Comorbidity, Depressive Disorder, Major, Dysthymic Disorder, Female, Humans, Male, Middle Aged, Psychotherapy, Comparative Study, Journal Article, Randomized Controlled Trial",
author = "Elisabeth Schramm and Levente Kriston and Ingo Zobel and Josef Bailer and Katrin Wambach and Matthias Backenstrass and Klein, {Jan Philipp} and Dieter Schoepf and Knut Schnell and Antje Gumz and Paul Bausch and Thomas Fangmeier and Ramona Meister and Mathias Berger and Martin Hautzinger and Martin H{\"a}rter",
year = "2017",
month = mar,
day = "1",
doi = "10.1001/jamapsychiatry.2016.3880",
language = "English",
volume = "74",
pages = "233--242",
journal = "JAMA PSYCHIAT",
issn = "2168-622X",
publisher = "American Medical Association",
number = "3",

}

RIS

TY - JOUR

T1 - Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression

T2 - A Randomized Clinical Trial

AU - Schramm, Elisabeth

AU - Kriston, Levente

AU - Zobel, Ingo

AU - Bailer, Josef

AU - Wambach, Katrin

AU - Backenstrass, Matthias

AU - Klein, Jan Philipp

AU - Schoepf, Dieter

AU - Schnell, Knut

AU - Gumz, Antje

AU - Bausch, Paul

AU - Fangmeier, Thomas

AU - Meister, Ramona

AU - Berger, Mathias

AU - Hautzinger, Martin

AU - Härter, Martin

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Importance: Chronic depression is a highly prevalent and disabling disorder. There is a recognized need to assess the value of long-term disorder-specific psychotherapy.Objective: To evaluate the efficacy of the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) compared with that of nonspecific supportive psychotherapy (SP).Design, Setting, and Participants: A prospective, multicenter, evaluator-blinded, randomized clinical trial was conducted among adult outpatients with early-onset chronic depression who were not taking antidepressant medication. Patients were recruited between March 5, 2010, and October 16, 2012; the last patient finished treatment on October 14, 2013. Data analysis was conducted from March 5, 2014, to October 27, 2016.Interventions: The treatment included 24 sessions of CBASP or SP for 20 weeks in the acute phase, followed by 8 continuation sessions during the next 28 weeks.Main Outcomes and Measures: The primary outcome was symptom severity after 20 weeks (blinded observer ratings) as assessed by the 24-item Hamilton Rating Scale for Depression (HRSD-24). Secondary outcomes were rates of response (reduction in HRSD-24 score of ≥50% from baseline) and remission (HRSD-24 score ≤8), as well as self-assessed ratings of depression, global functioning, and quality of life.Results: Among 622 patients assessed for eligibility, 268 were randomized: 137 to CBASP (96 women [70.1%] and 41 men [29.9%]; mean [SD] age, 44.7 [12.1] years) and 131 to SP (81 women [61.8%] and 50 men [38.2%]; mean [SD] age, 45.2 [11.6] years). The mean (SD) baseline HRSD-24 scores of 27.15 (5.49) in the CBASP group and 27.05 (5.74) in the SP group improved to 17.19 (10.01) and 20.39 (9.65), respectively, after 20 weeks, with a significant adjusted mean difference of -2.51 (95% CI, -4.16 to -0.86; P = .003) and a Cohen d of 0.31 in favor of CBASP. After 48 weeks, the HRSD-24 mean (SD) scores were 14.00 (9.72) for CBASP and 16.49 (9.96) for SP, with an adjusted difference of -3.13 (95% CI, -5.01 to -1.25; P = .001) and a Cohen d of 0.39. Patients undergoing CBASP were more likely to reach response (48 of 124 [38.7%] vs 27 of 111 [24.3%]; adjusted odds ratio, 2.02; 95% CI, 1.09 to 3.73; P = .03) or remission (27 of 124 [21.8%] vs 14 of 111 [12.6%]; adjusted odds ratio, 3.55; 95% CI, 1.61 to 7.85; P = .002) after 20 weeks. Patients undergoing CBASP showed significant advantages in most other secondary outcomes.Conclusions and Relevance: Highly structured specific psychotherapy was moderately more effective than nonspecific therapy in outpatients with early-onset chronic depression who were not taking antidepressant medication. Adding an extended phase to acute psychotherapy seems promising in this population.Trial Registration: clinicaltrials.gov Identifier: NCT00970437.

AB - Importance: Chronic depression is a highly prevalent and disabling disorder. There is a recognized need to assess the value of long-term disorder-specific psychotherapy.Objective: To evaluate the efficacy of the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) compared with that of nonspecific supportive psychotherapy (SP).Design, Setting, and Participants: A prospective, multicenter, evaluator-blinded, randomized clinical trial was conducted among adult outpatients with early-onset chronic depression who were not taking antidepressant medication. Patients were recruited between March 5, 2010, and October 16, 2012; the last patient finished treatment on October 14, 2013. Data analysis was conducted from March 5, 2014, to October 27, 2016.Interventions: The treatment included 24 sessions of CBASP or SP for 20 weeks in the acute phase, followed by 8 continuation sessions during the next 28 weeks.Main Outcomes and Measures: The primary outcome was symptom severity after 20 weeks (blinded observer ratings) as assessed by the 24-item Hamilton Rating Scale for Depression (HRSD-24). Secondary outcomes were rates of response (reduction in HRSD-24 score of ≥50% from baseline) and remission (HRSD-24 score ≤8), as well as self-assessed ratings of depression, global functioning, and quality of life.Results: Among 622 patients assessed for eligibility, 268 were randomized: 137 to CBASP (96 women [70.1%] and 41 men [29.9%]; mean [SD] age, 44.7 [12.1] years) and 131 to SP (81 women [61.8%] and 50 men [38.2%]; mean [SD] age, 45.2 [11.6] years). The mean (SD) baseline HRSD-24 scores of 27.15 (5.49) in the CBASP group and 27.05 (5.74) in the SP group improved to 17.19 (10.01) and 20.39 (9.65), respectively, after 20 weeks, with a significant adjusted mean difference of -2.51 (95% CI, -4.16 to -0.86; P = .003) and a Cohen d of 0.31 in favor of CBASP. After 48 weeks, the HRSD-24 mean (SD) scores were 14.00 (9.72) for CBASP and 16.49 (9.96) for SP, with an adjusted difference of -3.13 (95% CI, -5.01 to -1.25; P = .001) and a Cohen d of 0.39. Patients undergoing CBASP were more likely to reach response (48 of 124 [38.7%] vs 27 of 111 [24.3%]; adjusted odds ratio, 2.02; 95% CI, 1.09 to 3.73; P = .03) or remission (27 of 124 [21.8%] vs 14 of 111 [12.6%]; adjusted odds ratio, 3.55; 95% CI, 1.61 to 7.85; P = .002) after 20 weeks. Patients undergoing CBASP showed significant advantages in most other secondary outcomes.Conclusions and Relevance: Highly structured specific psychotherapy was moderately more effective than nonspecific therapy in outpatients with early-onset chronic depression who were not taking antidepressant medication. Adding an extended phase to acute psychotherapy seems promising in this population.Trial Registration: clinicaltrials.gov Identifier: NCT00970437.

KW - Adult

KW - Ambulatory Care

KW - Chronic Disease

KW - Cognitive Therapy

KW - Comorbidity

KW - Depressive Disorder, Major

KW - Dysthymic Disorder

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Psychotherapy

KW - Comparative Study

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1001/jamapsychiatry.2016.3880

DO - 10.1001/jamapsychiatry.2016.3880

M3 - SCORING: Journal article

C2 - 28146251

VL - 74

SP - 233

EP - 242

JO - JAMA PSYCHIAT

JF - JAMA PSYCHIAT

SN - 2168-622X

IS - 3

ER -